前立腺疾患におけるγ-Seminoproteinの臨床的研究 第1報: 血清中γ-Seminoprotein値の検討

Abstract

1)未治療前立腺癌群では前立腺肥大症群に比し血清中γ-Sm値は有意に高値を示した.その平均値はstageの進行とともに高値となり, 陽性率は高率となった.2)前立腺癌の検出率は, 血清中γ-Sm値とPAP値を同時に測定することにより向上した.3)転移性前立腺癌2例では, 血清中γ-Smはcutt off値以下であった.4)前立腺に強い炎症反応がおこると, 血清中γ-Sm値が高値となる可能性がある.5)前立腺癌の再燃の診断に血清中γ-Sm値は有用であるが, 治療効果の判定は, 他のマーカーなどと総合的に判断する必要がある

Serum gamma-seminoprotein (gamma-Sm) in patients with prostatic disease was determined by enzyme immunoassay. A total of 136 patients including 13 untreated and 40 treated patients with prostatic cancer, 45 patients with benign prostatic hyperplasia (BPH) and 38 patients with other urological diseases were analyzed. The mean +/- SD of serum gamma-Sm in the 13 patients with untreated prostatic cancer and the 45 patients with BPH was 31.7 +/- 46.1 and 3.7 +/- 6.6 ng/ml, respectively, there being a statistically significant difference between the two groups. All patients with untreated stage A or B prostatic cancer had a serum gamma-Sm of less than 4 ng/ml (cut off value). The mean level of serum gamma-Sm was 5.1 +/- 1.9 ng/ml for all patients with untreated stage C prostatic cancer; 66% of them had a value above the cut off value. However, it was 55.9 +/- 52.6 ng/ml in all patients with untreated stage D prostatic cancer; 87.5% of them had a value above the cut-off value. These results suggest that gamma-Sm may be a useful tumor marker in the management of patients with prostatic cancer.